ArticleBeilstein journal of organic chemistry2020
Fabclavine diversity in
Article in Beilstein journal of organic chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Article
- Mitigation of chytridiomycosis onMicrobiology spectrum · 2025Article
- Quorum sensing regulators and non-ribosomal peptide synthetases govern antibacterial secretions inFrontiers in microbiology · 2025Article
- Harnessing Gram-negative bacteria for novel anti-Gram-negative antibiotics.Microbial biotechnology · 2024Review
- ExploringMolecules (Basel, Switzerland) · 2024Review
- Antimicrobial Peptides (AMP) in the Cell-Free Culture Media ofAntibiotics (Basel, Switzerland) · 2023Article
- Metabolites of Xenorhabdus bacteria are potent candidates for mitigating amphibian chytridiomycosis.AMB Express · 2023Article
- XENOFOOD-An Autoclaved Feed Supplement Containing Autoclavable Antimicrobial Peptides-Exerts Anticoccidial GI Activity, and Causes Bursa Enlargement, but Has No Detectable Harmful Effects in Broiler Cockerels despite In Vitro Detectable Cytotoxicity on LHM Cells.Pathogens (Basel, Switzerland) · 2023Article
- Review
- Antiprotozoal activity of different Xenorhabdus and Photorhabdus bacterial secondary metabolites and identification of bioactive compounds using the easyPACId approach.Scientific reports · 2022Article
- Natural products from Photorhabdus and Xenorhabdus: mechanisms and impacts.Applied microbiology and biotechnology · 2022Review
- Type Strains of Entomopathogenic Nematode-Symbiotic Bacterium Species,Pathogens (Basel, Switzerland) · 2022Review
- Complex peptide natural products: Biosynthetic principles, challenges and opportunities for pathway engineering.Synthetic and systems biotechnology · 2022Article
- Beyond Soil-Dwelling Actinobacteria: Fantastic Antibiotics and Where to Find Them.Antibiotics (Basel, Switzerland) · 2022Review
- Nematophilic bacteria associated with entomopathogenic nematodes and drug development of their biomolecules.Frontiers in microbiology · 2022Review
- Editorial: New Antimicrobial Peptides From Bacteria/Invertebrate Obligate Symbiotic Associations.Frontiers in microbiology · 2022Article
- Metabonomics reveals that entomopathogenic nematodes mediate tryptophan metabolites that kill host insects.Frontiers in microbiology · 2022Article
- Antifungal activity of different Xenorhabdus and Photorhabdus species against various fungal phytopathogens and identification of the antifungal compounds from X. szentirmaii.Applied microbiology and biotechnology · 2021Article
- Structure and biosynthesis of deoxy-polyamine in Xenorhabdus bovienii.Journal of industrial microbiology & biotechnology · 2021Article
- Relative potency of a novel acaricidal compound from Xenorhabdus, a bacterial genus mutualistically associated with entomopathogenic nematodes.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global threat of multiresistant pathogens has to be answered by the development of novel antibiotics. Established antibiotic applications are often based on so-called secondary or specialized metabolites (SMs), identified in large screening approaches. To continue this successful strategy, new sources for bioactive compounds are required, such as the bacterial genera
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.